Drug Trial Radar · NCT01996839
Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Last checked: Nov 19, 2026Latest source record: Sep 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
514
Actual
Start
Dec 2013
Primary completion
May 2014
Study completion Jul 2014
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Nov 27, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate ophthalmic gel
Conditions
- Inflammation
- Pain
- Cataract
Interventions
Loteprednol Etabonate Gel (BID)Drug
One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
Loteprednol Etabonate Gel (TID)Drug
One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.
Vehicle (BID)Drug
One drop of vehicle instilled into the study eye two times per day (BID) for 14 days
Vehicle (TID)Drug
One drop of vehicle instilled into the study eye three times per day (TID) for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Complete Resolution of Anterior Chamber (AC) CellsTime frame: 8 days
- Percentage of Participants With Grade 0 Pain in the Study Eye.Time frame: 8 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bausch & Lomb Incorporated
Bridgewater, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.